BioMarin Pharmaceutical

  • 3 PDUFA Dates That Will Kickoff 2014

    By Brandy Betz - August 19, 2013 | Tickers: AZN, BMRN, BMY

    The phrase “PDUFA date” is thrown around frequently when discussing biotech and pharma companies. PDUFA stands for the Prescription Drug User Fee Act, which is a law allowing the Food and Drug Administration to charge companies that file new drug applications. The money goes towards expediting the review process that takes six months for drugs with an accelerated approval and ten months for a standard filing. Adding the appropriate number more »

  • Why Catalyst Pharmaceutical Partners Is Rising On Heavy Trading

    By ned reding - August 11, 2013 | Tickers: ACAD, BMRN, CPRX, PFE

    On April 18th shares of Catalyst Pharmaceutical Partners (NASDAQ: CPRX) began spiking on heavy volume trading from $.47 to slightly over $1.00 in just three days. Since then, buying has remained heavy almost every day with the price recently hitting $1.61. Shares appear to be in a consolidation and are holding well over $1.20. Catalyst only has about 42 million shares outstanding, but since April 18 more »

  • Orphan Drug Makers: Robust Investment Opportunities

    By Muhammad Abdullah - August 1, 2013 | Tickers: AEGR, BMRN, ISIS

    The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases. So the concept of an orphan drug is no more a mystery for the people who invest into pharmaceutical companies. According to the findings of Thomson Reuters, at the end of 2011 orphan drug sales attributed to 6% of the total pharmaceutical sales. Along with that more »

  • Exploding Pipeline Makes BioMarin Attractive Takeover Target

    By colin simpson - July 11, 2013 | Tickers: BMRN, PFE, SNY

    The Orphan Drug pipeline of BioMarin Pharmaceutical (NASDAQ: BMRN) has been growing so rapidly that the company has been the object of many takeover rumors since 2006 when it was believed that Genzyme was eyeing them for a buyout. No buyout has occurred yet, but rumors persist and since 2006, shares have risen from $3.87 to over $70.  Further supporting this potential buyout is that Genzyme has been acquired more »

  • What Makes a Good Orphan Drug Investment?

    By Sherrie Stone - June 28, 2013 | Tickers: ALXN, BMRN, RPTP

    Orphan drug companies are an exciting new class in the healthcare sector -- with good and bad investment opportunities -- let's look at the differences.

    What is an Orphan?

    The word “Orphan’ in biotechnology creates excitement! It means that a company has more years of exclusivity on a product and it also indicates that a company’s technology is beyond the norm.

    Orphan indications are not earned easily, as companies must more »

  • Don't Miss These 3 Companies With High Earnings-Per-Share Forecasts

    By Madhukar Dubey - June 24, 2013 | Tickers: MT, BMRN, LNKD

    Earnings per share, or EPS, is an important metric for investors performs a lot of functions: It helps suggest potential profits on individual shares in a company. Moreover, it also shows the performance of a company in a given timeframe, and annual EPS growth suggests the cash generation capacity of a company.

    Here are three companies with annual EPS growth forecast above 25% for five years – but they'll only more »

  • Highlights from the Goldman Sachs Healthcare Conference

    By John Macris - June 18, 2013 | Tickers: AET, BMRN, XLV

    Goldman Sachs recently hosted its 34th Annual Global Healthcare Conference on June 11 – 13 in Rancho Palos Verdes, CA.

    Healthcare was considered a defensive sector during the 2008–09 recession, but I believe it will continue to perform going forward. An aging baby boomer population, the Obamacare rollout, and a growing need for disease treatments should lead to profitable investing for many years to come.

    The Health Care Select Sector more »

  • Post-ASCO Movers: Are Any a Buy?

    By Brian Nichols - June 5, 2013 | Tickers: BMRN, CLVS, SNTA

    Late last year, Clovis Oncology (NASDAQ: CLVS) saw its share price cut in half, to $11.50, after reporting that its Phase 3 drug CO-101 failed to show a benefit over chemotherapy. The company said it was shutting down the development of the trial and was going to focus on its pipeline.

    Now, Clovis Oncology is trading near $73 with gains of more than 100%. The gains followed exceptional data more »

  • 3 Significant Insider Sells in Healthcare Worth Noting

    By Brian Nichols - May 31, 2013 | Tickers: BMRN, REGN, VRTX

    It’s no secret that the insiders of a company know what’s happening before us. They know trends, demand, supply, and to most of us, it makes no sense for an executive to sell shares prior to a large takeover or raised earnings guidance. Thus, when an insider sells shares we automatically assume the worst – and in some cases – we are correct!

    Two Examples of Insider Selling

    While investors more »

  • Catalyst Pharmaceuticals Successfully Repositions In Hot Orphan Drug Space

    By Michael Anderson - May 23, 2013 | Tickers: ALXN, BMRN, CPRX, PFE, SNY

    I was surprised to see Catalyst Pharmaceutical Partners, (NASDAQ: CPRX) Inc. break out to the upside following the announcement last November of disappointing results from the latest clinical trial of CPP-109 for cocaine addiction. After forming a solid base around $.50 for the past three months, Catalyst spiked to $1.06 and is now consolidating its' gain.  Technically, Catalyst looks like it is getting ready for another big advance.

    <img src="http://g.fool.com/editorial/images/44402/z_large.png" />

    I more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 19, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long-lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drugs. You might ask why you should bother investing in this type of biotech stocks? Because these companies treat rare diseases with limited treatment options. 

    In my opinion, these biotech stocks perform better than their peers, and will more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 16, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drug status. You might ask why invest in these types of biotech stocks? It is quite simple really, these types of companies treat rare diseases with limited treatment options. 

    In my opinion I feel these biotech stocks more »

  • How to Play the Immediate Uncertainty of this Promising Biotech Stock

    By Brian Nichols - April 7, 2013 | Tickers: ALXN, BMRN, SRPT

    Sarepta Therapeutics (NASDAQ: SRPT) has been one of the best performing stocks of the last year, and has among the greatest level of promise in the biotechnology industry. However, it faces immediate uncertainty, and because of that uncertainty I am exploring the best way to play the stock.

    A 50/50 Chance is a Gamble

    Sarepta Therapeutics has been volatile over the last few sessions, but saw a 5.17 more »

  • This Mid-Cap Pharmaceutical is a Prime Takeover Target

    By John Macris - February 16, 2013 | Tickers: BMRN, SNY, SRPT

    How many of us as investors want to identify companies that are pioneers in their industry? Is it possible to find commonality across sectors, which factors make specific companies great and cause other companies to fail?

    A technology company like Oracle, which despite its tremendous size, continues to innovate and deliver value for shareholders by making smart bolt-on acquisitions. Or consider multimedia and entertainment giant Walt Disney, led by the more »

  • Hedge Fund Zweig Dimenna’s Stock Picks for 2013 Include Apple

    By Meena Krishnamsetty - February 10, 2013 | Tickers: AIG, AAPL, BMRN, GOOG, V

    Zweig Dimenna was founded in 1984 by Martin Zweig and Joe DiMenna. The hedge fund recently filed its 13F for fourth quarter of 2012, disclosing many of its long equity positions as of the end of December (and, therefore, the stocks it owned going into 2013). Our research has shown that investors could have outperformed the market significantly by imitating the most popular stock picks of hedge funds (see the more »

  • Are You Missing The Upside Potential Here?

    By Jordo Bivona - December 19, 2012 | Tickers: ACAD, AEZS, BMRN

    There are many biotech stocks that have "popped" on positive drug trial data. But it is clear that many investors are not factoring in the upside potential of these biotech companies that are highly levered in terms of valuation. Below, I will examine three companies that appear to be undervalued in light of clinical trial data. Specifically, I will focus on Acadia Pharmaceuticals (NASDAQ: ACAD)Aeterna Zentaris (NASDAQ: AEZS), and more »

  • Biotech's Next Major Pullback

    By Brian Nichols - December 11, 2012 | Tickers: ALXN, BMRN, PCYC, REGN

    There’s no denying that biotechnology is the ultimate industry of momentum, where companies often trade with multi-year rallies, reaching valuations that can not possibly be explained. In the last six months we have witnessed the fall of Alexion Pharmaceuticals (NASDAQ: ALXN) from its multi-year rally, and in this article I am looking at which companies might be next.  

    Back in October Alexion Pharmaceuticals reached an all-time high of $119 more »

  • Pharmacyclics Trick Proves to be Wise

    By Brian Nichols - November 7, 2012 | Tickers: BMRN, PCYC

    If you woke up on Monday morning and saw the headline news from Pharmacyclics (NASDAQ: PCYC) then you probably felt pretty good. However, aside from strong quarterly results were two pieces of information that caused selling pressure throughout the day.

    Pharmacyclcs beat earnings expectations with $102.7 million in revenue and an EPS of $1.06. The company’s bottom line expectations have come under question, as investors have questioned more »

  • BioMarin Still Presents Upside Despite Gains

    By Brian Nichols - November 6, 2012 | Tickers: ALXN, BMRN

    BioMarin Pharmaceuticals (NASDAQ: BMRN) is a biotechnology company with very modest sales growth, is not profitable, and trades with a valuation that implies it to be one of the faster growing companies in biotechnology. The company, which sports a price/sales ratio of 9.72, is priced expensively because of its pipeline and its potential. On Monday the company’s stock traded higher by 30% after positive results from its more »

  • Bio Buyouts

    By AnnaLisa Kraft - July 28, 2012 | Tickers: ALXN, BMRN, IDIX, REGN, VRTX

    For biotech investors a positive phase III clinical trial is like a home run, an FDA approval is like a game winning grand slam but a buyout is like winning the World Series with fireworks, rainbows and unicorns. (OK, not unicorns). A buyout is what every biotech investor dreams of and over this last year there have been some monster buyouts.

    Biotech is usually about binary events like FDA approvals more »

  • Page 1 of 2